CHEMOTHERAPY FOUNDATION SYMPOSIUM
INNOVATIVE CANCER THERAPY FOR TOMORROW®
The Greenspan Meeting XXIX

Presented by
The Chemotherapy Foundation
and the
Page & William Black Post-Graduate School
of the
Mount Sinai School of Medicine

NOVEMBER 8-12, 2011
Tuesday-Saturday

MARRIOTT MARQUIS HOTEL
NEW YORK CITY, USA

Franco M. Muggia, M.D.
Chair
Edward P. Ambinder, M.D.
Program Director & Associate Chair
Janice L. Gabrilove, M.D.
Associate Chair
William K. Oh, M.D.
Associate Chair

A Continuing Education Program of
The Chemotherapy Foundation

www.chemotherapyfoundationsymposium.org

Conference Management Director: Jaclyn Silverman
HISTORY

In Honored Memory
Ezra M. Greenspan, M.D.
1919-2004
Founder of the
Chemotherapy Foundation Symposium
A Pioneering Trailblazer whose Achievements are
the Legacy of every Practicing Oncologist Today

A LOOK BACKWARD AND AHEAD

In its fourth decade the Chemotherapy Foundation Symposium, that began as a local cancer seminar in 1972, attracts a worldwide audience of oncologists and hematologists from the United States and Canada joined by colleagues from Nigeria, Armenia, Australia, China, the Ukraine, France, England, Croatia, Germany, Italy, Spain, Japan, Lebanon, Korea, Taiwan, Latin America, and many other countries to learn of new developments in cancer therapy.

In 1968, when oncology was a newly developing specialty for the treatment of cancer, Dr Ezra M. Greenspan, founded The Chemotherapy Foundation to raise seed money to support innovative cancer research projects. A passionate advocate for the promise of combination chemotherapy, he launched the Chemotherapy Foundation Symposium to provide a forum for clinical investigators to report on the clinical studies of new agents and regimens proving effective in managing cancer patients.

At the first Symposium in 1972, about one hundred oncologists were introduced to the emerging field of chemoimmuno-therapy. In 1984, several hundred more oncologists were present at the first Breast Cancer Chemoprevention conference advocating clinical trials of the then newly introduced antiestrogen tamoxifen for high-risk women, a vision that was realized in the next decade with the NSABP clinical trials. Then as now, Symposium presentations have focused on practical applications for the medical oncologist.

As we enter the era of molecular targeted therapies, genomics, vaccines and other biotechnological strategies that will turn cancer from a life-threatening illness to a treatable chronic disease, we continue the mission of Ezra Greenspan whose goal was the continuing education of the oncologists who would bring the advances in oncology to better patient care and outcomes.

Innovative Cancer Therapy for Tomorrow presentations will continue to explore the significance of the new developments and the challenge of broadening the therapeutic agenda for management of cancer patients.
CONTINUING EDUCATION

PROGRAM GOALS
The extensive scope and intensive coverage of new developments in cancer therapeutics at this annual educational activity provide cancer care providers with the opportunity to learn about the new agents, new modalities, clinical trials and emerging developments that will result in continuing progress in the control and cure of cancer.

LEARNING OBJECTIVES
At the conclusion of the program, participants should be able to:
1. Evaluate the potential benefits of the emerging developments in cancer therapy.
2. Employ new concepts, agents and regimens in cancer patient management to achieve better outcomes.
3. Inform patients of improved treatment options and the benefits of enrollment in clinical trials.

TARGET AUDIENCE
Oncologists, Hematologists, Breast Cancer Oncologists, Gynecological Oncologists, Surgical Oncologists, Pediatric Oncologists, Radiotherapists, Immunologists, Oncology Nurses, Nurse Practitioners, Physician Assistants, Case Managers, Pharmacists.

ACCREDITATION
Physicians
The Mount Sinai School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
The Mount Sinai School of Medicine designates this live activity for a maximum of 34.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Oncology Nurses, Nurse Practitioners, Physician Assistants, Case Managers
CME hours for the Tuesday through Friday sessions, November 8-11 may be submitted to credentialing organizations for acceptance of conversion to CE. Authorized CE contact hours for Saturday, November 12 will be determined by accrediting organizations. Applications are pending for Submission to Postgraduate Institute for Medicine (PIM), an accredited provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation, the American Academy of Physician Assistants. Case managers may submit their ANCC credit to their respective organization.

Pharmacists
Pharmacists will be eligible for CEU’s for the Tuesday-Friday sessions, November 9-12 plus additional contact hours for the Saturday session on November 13 provided by the New York State Council of Health-System Pharmacists (NYSCHP) an approved provider of continuing pharmaceutical education by the Accreditation Council for Pharmaceutical Education (ACPE). Total number of contact hours available to pharmacists will be 34.5. Certification of Attendance will be provided to all professionals.

FACULTY DISCLOSURE POLICY
It is the policy of the Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency and scientific rigor in all CME sponsored educational activities. All faculty participating in the planning or implementation of a supported activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict-of-interest that may arise from the situation. Presenters must also make a meaningful disclosure to the audience in their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.
**CONFERENCE HOTEL RATE REDUCTION!**

*Marriott Marquis $359 per night • Millennium $329 per night*

**REGISTRATION FEES**

- **$525** Physicians
- **$150** House Staff, Fellows, Oncology Nurses, Nurse Practitioners, Physician Assistants, Case Managers, Pharmacists and other Cancer Care Providers.
- **$50** Tuesday Only*
- **$50** Saturday Only*
- **$50** Mount Sinai and Affiliated Institutions. *No fee is required for Tuesday or Saturday if you are registering for the entire Symposium. Payment may be made by check or credit card.
- **$50** Oncology Practice Administrators

**FAX Registration Form. On Line Registration not Available**

**REFUND POLICY**

A 10% Administrative Charge plus the $15 processing fee will be deducted from all refunds issued. REQUESTS FOR REFUNDS RECEIVED AFTER November 3 will not be honored by the Post Graduate School of Mount Sinai.

**HOTELS**

The NEW YORK MARRIOTT MARQUIS located on Broadway between 45th and 46th Streets in midtown Manhattan is the Headquarters Hotel and Symposium site. Blocks of rooms at special conference rates have been set aside for symposium attendees at the Marriott and the Millennium Hotels. A block of rooms at the special conference rate of $359 per night has been reserved at the Marriott for Symposium attendees. The spacious ballroom with seating capacity for over 2,000 and large Exhibitor Pavilion make this an ideal site for all Symposium activities.

The Millennium Hotel is located on West 44th Street off Broadway about a block away from the Symposium Site. A block of rooms at the special conference rate of $329 per night has been reserved at the Millennium for Symposium attendees. Both hotels are a short bus, taxi ride or easy walk to New York City’s major attractions. Please identify yourself as a Chemotherapy Foundation Symposium attendee when making your hotel reservations. **Please make your reservations early to take advantage of special Conference Rates.**

TO MAKE ARRANGEMENTS FOR ALTERNATIVE HOTEL ACCOMMODATIONS, PLEASE CONTACT OUR HOUSING MANAGER, DENISE NEWMAN: Dnew229@aol.com TEL 718 835 4911, FAX 718 835 8661.

**EARLY BIRD REGISTRATION**

Tuesday, November 8, 2 PM-9 PM

Prior and New Registrants: Avoid the first-day rush on Wednesday morning. Sign-in Tuesday and pick up your Symposium Kits with the Abstracts and other meeting materials.

**WELCOME BACK NEXT YEAR**

**NOVEMBER 6-10, 2012**
TUESDAY, NOVEMBER 8

PEDIATRIC ONCOLOGY
Chair: Robert Maki, MD, PhD
1:30 BONE MARROW TRANSPLANT FOR METABOLIC DISEASE
Vinod K. Prasad, MD, MRCP
1:45 ADVANCES IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
Blythe G. Thomson, MD
2:00 FINDING CURES FOR CHILDREN AT HOME AND ABROAD: SYNERGY IN LOW, MIDDLE, AND HIGH-INCOME COUNTRIES
Scott C. Howard, MD
2:15 CLINICAL TRIAL METHODS FOR RARE CANCERS
J. Kyle Wathen, PhD
2:30 NOVEL THERAPEUTICS I: NOTCH AND WNT SIGNALING PATHWAYS IN PEDIATRIC MALIGNANCIES
Lia Gore, MD
2:45 NOVEL THERAPEUTICS II: AN APPROACH TO MELANOMA THERAPY EMPLOYING SYNTHETIC BIOLOGY
Ronald B. Herberman, MD
3:00 Coffee Break
3:15 THE ROLE OF SURVEILLANCE IN THE MANAGEMENT OF STAGE I GERM CELL TUMORS
Matthew D. Galsky, MD
3:30 INTRA-ARTERIAL CHEMOTHERAPY FOR INTRA-OCULAR RETINOBLASTOMA
Ira J. Dunkel, MD
3:45 RECENT ADVANCES IN NEUROBLASTOMA THERAPY
Brian H. Kushner, MD
4:00 CURRENT MANAGEMENT OF RHABDOMYOSARCOMA
Alberto S. Pappo, MD
4:15 OSTEOSARCOMA: CLINICAL TRIALS
Richard G. Gorlick, MD
4:45 OncEd and Discussion

We appreciate the indispensable role of Gustave Del Toro in developing the Pediatric Oncology Program of the Chemotherapy Foundation Symposium.

Conference Highlights

Wednesday Keynote Speaker
James F. Holland, MD

Thursday Ezra M. Greenspan Memorial Lecture
Martine Piccart, MD

Friday Judah Folkman Memorial Lecture
Norman Wolmark, MD
WEDNESDAY, NOVEMBER 9

7:00  Breakfast with the Professors
     STATUS OF PCI 32765 IN CLL AND ITS POTENTIAL ROLE IN LYMPHOMA
     John Byrd, MD
     IMIDS IN MULTIPLE MYELOMA
     Kenneth Anderson, MD

8:00  WELCOME
     Edward Ambinder, MD, Steven Burakoff, MD, Janice Gabrilove, MD

MORNING SESSION

HEMATOLOGIC MALIGNANCIES
Moderators: Janet Cuttner, MD, Janice L. Gabrilove, MD, Kanti Rai, MD

Myeloproliferative Disease (MPD)
8:10  JAK INHIBITORS: UPDATE AND EVALUATION
     Richard Silver, MD
8:25  DRUG COMBINATIONS FOR MYELOPROLIFERATIVE NEOPLASMS
     Ronald Hoffman, MD

Myelodysplastic Syndrome (MDS)
8:40  UNIFYING THEMES IN EVOLVING CLINICAL AND BIOLOGIC INSIGHTS
     Azra Raza, MD

ALL
8:55  MONOCLONAL ANTIBODIES: TARGETED THERAPIES
     Hagop Kantarjian, MD

AML
9:10  MOLECULAR PROFILING IN AML: CLINICAL IMPLICATIONS
     Janice Gabrilove, MD
9:25  MOVING BEYOND “7 AND 3”- NEW TREATMENT STANDARDS
     Gail Roboz, MD
9:40  STUDIES OF CPX-351
     Jeffrey Lancet, MD

CLL
9:55  OVERVIEW OF NEW DRUGS
     Kanti Rai, MD
10:10 Coffee Break

CML
10:40 SECOND GENERATION TYROSINE INHIBITORS VS IMATINIB: FRONT LINE
     Jorge Cortes, MD

Lymphomas
10:55  NOVEL AGENTS IN HODGKIN’S LYMPHOMA
     Anas Younes, MD
11:10 NEW APPROACHES IN MANTLE CELL LYMPHOMA
     John Leonard, MD

Multiple Myeloma
11:25 CARLIFILZOMIB AND OTHER NEW PROTEOSOME INHIBITORS
     James Berenson, MD
11:40 OncEd and Discussion
### Wednesday, NOVEMBER 9 continued

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Lunch &amp; Presentations</td>
<td>Charles Blanke, MD</td>
</tr>
<tr>
<td></td>
<td>STATE OF THE ART IN GIST: ADJUVANT THERAPY AND MUTATIONAL ANALYSIS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IS THERE ROOM FOR OTHER ANGIOGENESIS INHIBITORS?</td>
<td>Jordan Berlin, MD</td>
</tr>
<tr>
<td></td>
<td><strong>AFTERNOON SESSION</strong></td>
<td></td>
</tr>
<tr>
<td>1:15</td>
<td><strong>KEYNOTE SPEAKER</strong></td>
<td>James Holland, MD</td>
</tr>
<tr>
<td></td>
<td>THE ONCOLOGIC TIME WARP</td>
<td></td>
</tr>
<tr>
<td>1:50</td>
<td><strong>ANTI-TUMORAL RATIONALS</strong></td>
<td>Olivier Rixe, MD</td>
</tr>
<tr>
<td></td>
<td>ANTIBODY-DRUG-CONJUGATES (ADC)</td>
<td></td>
</tr>
<tr>
<td>2:05</td>
<td><strong>COLORECTAL CANCER</strong></td>
<td>Emily Chan, MD</td>
</tr>
<tr>
<td></td>
<td>FOLFIRI+CETUXIMAB IN ADJUVANT THERAPY</td>
<td></td>
</tr>
<tr>
<td>2:20</td>
<td>VEGF-TRAP: A NEW PLAYER IN ANGIOGENESIS</td>
<td>Paolo Hoff, MD</td>
</tr>
<tr>
<td>2:35</td>
<td>ACTIVE NEW AGENTS</td>
<td>John Marshall, MD</td>
</tr>
<tr>
<td>2:50</td>
<td><strong>Coffee Break</strong></td>
<td></td>
</tr>
<tr>
<td>3:20</td>
<td><strong>GI CANCERS</strong></td>
<td>Leonard Saltz, MD</td>
</tr>
<tr>
<td></td>
<td>THE P13K PATHWAY</td>
<td></td>
</tr>
<tr>
<td>3:35</td>
<td>VITAMIN D: REDUCING CANCER RISK?</td>
<td>Marwan Fakih, MD</td>
</tr>
<tr>
<td>3:50</td>
<td>MOVING FORWARD IN THE ERA OF FOLFIRINOX</td>
<td>Eileen Mary O’Reilly, MD</td>
</tr>
<tr>
<td>4:05</td>
<td><strong>GASTRIC CANCER</strong></td>
<td>Deirdre Cohen, MD</td>
</tr>
<tr>
<td></td>
<td>THE HEDGEHOG INHIBITOR</td>
<td></td>
</tr>
<tr>
<td>4:20</td>
<td>TELATINIB IN ADVANCED GASTRIC CANCER</td>
<td>Jaffer Ajani, MD</td>
</tr>
<tr>
<td></td>
<td>GIST - ADJUVANT THERAPY AND MUTATIONAL ANALYSIS</td>
<td>Charles Blanke, MD</td>
</tr>
<tr>
<td>4:35</td>
<td><strong>HEPATOCELLULAR CANCER</strong></td>
<td>Hossein Borghaei, MD</td>
</tr>
<tr>
<td></td>
<td>NOVEL ANTIBODY TO ALK1 AFFECTING TGF BETA AND ANGIOGENESIS</td>
<td></td>
</tr>
</tbody>
</table>

**7-9 PM Dinner and Presentation**
THURSDAY, NOVEMBER 10

7:00  Breakfast with the Professors
      PROSPECTIVE ON THE LAST TWENTY FIVE YEARS:
      EMERGING EVIDENCE AND GENETIC STRATEGIES
      Franco Muggia, MD
      IMMUNOTHERAPY OF OVARIAN CANCER
      George Coukos, MD

MORNING SESSION
Moderators: Franco M. Muggia, MD, Carmel Cohen, MD, Tamar Safra, MD

GYNECOLOGICAL CANCERS
Ovarian Cancer
8:00  INTRAPERITONEAL THERAPY: CURRENT QUESTIONS
      Franco Muggia, MD
8:15  IMPACT OF BEVACIZUMAB ON FRONT LINE AND
      RECURRENCE IN OVARIAN CANCER
      Michael Bookman, MD
8:30  ACTIVE NEW AGENTS IN OVARIAN CANCER
      Bradley Monk, MD
8:45  PHASE 2 TRIAL OF EPITHELIAL OVARIAN CANCER
      TREATED WITH XL184
      Ronald Buckanovich, MD
9:00  RESULTS OF TWO PARP TRIALS
      Bhavana Pothuri, MD
9:15  ROLE OF DOXIL AND CARBOPLATIN IN
      SECOND LINE TREATMENT
      Tamar Safra, MD
9:30  OVERVIEW: STATUS OF ENDOMETRIAL CANCER
      Vicky Makker, MD
9:45  ISSUES IN TREATMENT OF RECURRENT OVARIAN CANCER IN
      THE ERA OF BEVACIZUMAB
      William McGuire, MD
10:00 Coffee Time
10:30 OncEd and Discussion

HEAD AND NECK CANCERS
Moderator: Missak Haigentz Jr., MD

Oropharynx
10:55  HPV RELATED CANCER
      Marshall Posner, MD

Thyroid
11:10  NEW AGENTS IN THYROID CANCER THERAPY
      Jochen Lorch, MD
11:25  CLINICAL HETEROGENEITY IN PAPILLARY
      THYROID CARCINOMA
      Kepal Patel, MD
11:40  OncEd and Discussion

12 Noon Lunch & Presentations
      OBESITY, AROMATASE INHIBITORS:
      THE CONNECTING LINKS
      Andrew Dannenberg, MD
      TOPIC TO BE ANNOUNCED
      Speaker to be Announced
THURSDAY, NOVEMBER 10

1:20 EZRA M. GREENSPAN MEMORIAL LECTURE
CURE OF HER2 POSITIVE BREAST CANCER WITH NO
OR MINIMAL CHEMOTHERAPY AT THE DOOR STEP?
Martine Piccart, MD

AFTERNOON SESSION
BREAST CANCER
Moderators: Harold Burstein, MD, Seymour Cohen, MD, George Raptis, MD

1:40 CIRCULATING TUMOR CELLS
Daniel Hayes, MD

1:55 UPDATE ON DATA REPORTS ON ANTI-HER2 THERAPY:
LAPATINIB+TRASTUZUMAB
Harold Burstein, MD

2:10 UPDATE ON PREVENTIVE EFFICACY OF AROMATASE INHIBITORS
Paul Goss, MD

2:25 PARP INHIBITION IN TRIPLE NEGATIVE BREAST CANCER
Daniel Silver, MD

2:40 NSABP DATA: BEVACIZUMAB FOR TRIPLE-NEGATIVE
BREAST CANCER
Adam Brufsky, MD

2:55 Coffee Time

3:25 SENTINAL LYMPH NODE BIOPSY: A SURGEON’S PERSPECTIVE
Hiram Cody, MD

3:40 SENTINAL LYMPH NODE BIOPSY:
AN ONCOLOGIST’S PERSPECTIVE
Clifford Hudis, MD

3:55 TAMOXIFEN AND CYP2D6: LOST IN TRANSLATION?
George Raptis, MD

4:10 EVALUATING SINGLE-AGENT NKTR-102 IN METASTATIC
BREAST CANCER
Edith Perez, MD

4:25 OncEd and Discussion

7-9 PM Dinner & Presentation
FRIDAY, NOVEMBER 11

7:00  Breakfast with the Professors
Chair: William Oh, MD
A VALIDATED WHOLE BLOOD RNA SIGNATURE FOR
SURVIVAL IN CRPC
William Oh, MD
MOLECULAR DIAGNOSTICS IN GU CANCERS:
CTCS AND BEYOND
CTCS: Overview and Applications in Bladder Cancer
Matt Galsky, MD
Prostate Cancer and CTCs: Are We Hitting the Target?
Daniel Danila, MD

MORNING SESSION
URO-ONCOLOGY
Moderators: Anna Ferrari, MD, William Oh, MD
Prostate Cancer
8:00  NEW AND NOVEL AGENTS
Oliver Sartor, MD
8:15  POMEGRANATE EXTRACT FOR RISING PSA
Michael Carducci, MD
8:30  XL184 IN METASTATIC CASTRATION RESISTANT
PROSTATE CANCER
David Smith, MD
8:45  OPTIMIZING PATIENT SELECTION FOR SIPULEUCEL-T
IN PROSTATE CANCER
Simon Hall, MD
9:00  INTERMITTENT ANDROGEN SUPPRESSION FOR
PROSTATE CANCER
Laurence Klotz, MD
9:15  LENOLIDOMIDE/DOCETAXEL IN CRPC
Daniel Petrylak, MD

Renal Cancer
9:30  AXINITIB IN RCC
Brian Rini, MD
9:45  PD-1 ANTI-BODY IN RCC
David McDermott, MD
10:00  Coffee Time

Bladder Cancer
10:15  NEW THERAPIES IN BLADDER CANCER
Noah Hahn, MD
10:30  OncEd and Discussion

LUNG CANCER
Moderators: Chandra P. Belani, MD, Roman Perez-Soler, MD
NSCLC
10:45  PERSONALIZED THERAPY AND RECENT CHANGES IN TREAT-
MENT PARADIGM
Chandra P. Belani, MD
11:10  ANTI-ANGIOGENIC AGENTS
Roman Perez-Soler, MD
SCLC
11:25  NOVEL AGENTS AND FUTURE DIRECTIONS:
Corey Langer, MD
11:40  OncEd and Discussion
FRIDAY, NOVEMBER 11 continued

12:00 Lunch & Presentations
Novel Agents in Lung Cancer
HDAC Inhibitors: Suresh Ramalingam
Talactoferrin: Jeffrey Crawford
MetMAb and ARQ 197: Paul Bunn, MD
Farletuzumab: Chandra P. Belani, MD

AFTERNOON SESSION

1:00 JUDAH FOLKMAN MEMORIAL LECTURE
ANTI-ANGIOGENESIS: PARADISE LOST?
Norman Wolmark, MD

DIVERSE TOPICS
Moderrators: Edward Ambinder, MD, Sylvia Adams, MD
1:20 SARCOMA MOLECULAR SIGNATURES:
CLASSIFICATION, RESPONSE, OUTCOMES
Paul Meltzer, MD
1:35 MELANOMA: NOVEL NEW AGENTS
Jeffrey Sosman, MD
1:50 BONE-TARGETED AGENTS: INTEGRATED EFFICACY
ANALYSIS IN SOLID TUMORS
Allan Lipton, MD
2:05 THE ELDERLY CANCER PATIENT: ASSESSMENT AND MANAGEMENT IN A SPECIAL-NEEDS POPULATION
Stuart Lichtman, MD
2:20 PREDICTIVE AND PROGNOSTIC TOOLS FOR EHR WEB APPS
Kevin Hughes, MD
2:35 NEW PRACTICE MODELS FOR ONCOLOGY
Peter Bach, MD
2:55 SAVING LIVE CME: WHAT CAN YOU DO?
Edward Ambinder, MD
3:15 WRAP UP

The collaboration of the Tisch Cancer Institute and the NYU Oncology Division in developing the Agenda for the 2011 Symposium is appreciated.

New Perspectives in Oncology Practice
Saturday, November 12, 8 AM - 4:25 PM

Empowering the Clinical Care Team
Oncology Nurses, Nurse Practitioners, Physician Assistants, Case Managers, Pediatric Oncology Nurses, Pharmacists

A Program Overview

Oncologic Emergencies
AML in Older Adults
Health Care Reform
Iron Overload
Cancer Pain Management
Cancer Care for Elderly
Bone Health in Cancer Survivors
New Drug Update
Triple Negative Breast Cancer
Adolescents and Young Adults
with Sarcoma
Compassion Fatigue
Radiation Therapy Skin Reactions
Postoperative Complications in Ovarian Cancer
Women's Risk Assessment
Providers and Patients in Cyberspace
SPECIAL EVENTS

NOV 9

Breakfast with the Professors
STATUS OF PCI 32765 IN CLL AND ITS POTENTIAL ROLE IN LYMPHOMA
John Byrd, MD
IMIDS IN MULTIPLE MYELOMA
Kenneth Anderson, MD

LUNCH AND PRESENTATIONS
STATE OF THE ART IN GIST: ADJUVANT THERAPY AND MUTATIONAL ANALYSIS
Charles Blanke, MD
IS THERE ROOM FOR OTHER ANGIGENESIS INHIBITORS?
Jordan Berlin, MD

KEYNOTER
THE ONCOLOGIC TIME WARP
James Holland, MD

NOV 10

Breakfast with the Professors
PROSPECTIVE ON THE LAST TWENTY FIVE YEARS: EMERGING EVIDENCE AND GENETIC STRATEGIES
Franco Muggia, MD
IMMUNOTHERAPY OF OVARIAN CANCER
George Coukos, MD

LUNCH AND PRESENTATIONS
OBESITY, AROMATASE INHIBITORS: THE CONNECTING LINKS
Andrew Dannenberg, MD
TOPIC TO BE ANNOUNCED
Speaker to be Announced

EZRA M. GREENSPAN MEMORIAL LECTURE
CURE OF HER2 POSITIVE BREAST CANCER WITH NO OR MINIMAL CHEMOTHERAPY AT THE DOOR STEP?
Martine Piccart, MD

NOV 11

Breakfast with the Professors
Chair: William Oh, MD
A VALIDATED WHOLE BLOOD RNA SIGNATURE FOR SURVIVAL IN CRPC
William Oh, Md
MOLECULAR DIAGNOSTICS IN GU CANCERS: CTCS AND BEYOND
CTCS: Overview and Applications in Bladder Cancer
Matt Galsky, MD
Prostate Cancer and CTCs: Are We Hitting the Target?
Daniel Danila, MD

LUNCH AND PRESENTATIONS
NOVEL AGENTS IN LUNG CANCER
HDAC Inhibitors,Suresh Ramalingam
Talactoferrin, Jeffrey Crawford
MetMAb, Paul Bunn, MD
Farletuzumab, Chandra Belani, MD
ARQ197, To be Announced

JUDAH FOLKMAN MEMORIAL LECTURE
ANTI-ANGIOGENESIS: PARADISE LOST?
Norman Wolmark, MD
CONFERENCE HIGHLIGHTS

Keynote Speaker
THE ONCOLOGIC TIME WARP
James Holland, MD, Wednesday, November 9

Ezra M. Greenspan Memorial Lecture
CURE OF HER2 POSITIVE BREAST CANCER WITH NO OR MINIMAL CHEMOTHERAPY AT THE DOOR STEP?
Martine Piccart, MD, Thursday, November 10

Judah Folkman Memorial Lecture
ANTI-ANGIOGENESIS: PARADISE LOST?
Norman Wolmark, MD, Friday, November 11

New
WIFI ACCESS
Wednesday through Friday
Conference Rooms and Exhibitor Areas
Free for All Symposium Attendees

PORTAMEETING
Take Home the Presentations
On the USB Storage Presentation Drive

OncEd Mini-Sessions
Selecting the Practice-Ready Therapies
Accessing Learning Resources
Expanding the Symposium Educational Experience

HOSPITALITY SUITE
Symposium-Eve, November 8, 7-9 PM

Your Patient Care Team will be interested in New Perspectives in Oncology Practice a Continuing Education program for Oncology Nurses, Nurse Practitioners, Physician Assistants, Case Managers and Pharmacists on Saturday, November 12. They may register and be accredited for the entire program including Saturday or attend on Saturday only. Programs will be sent on request.
Contact: Jaclyn.silverman@mssm.edu

Special Needs
Americans with Disabilities Act: Mount Sinai School of Medicine is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you would like to attend this conference and require any special needs or accommodations, please contact the Page and William Black Post-Graduate School of Medicine at 212-731-7950.
REGISTRATION

Chemotherapy Foundation Symposium
Innovative Cancer Therapy for Tomorrow®

The Greenspan Meeting XXIX
November 8-12, 2011
Pediatric Oncology November 8 / Nursing Oncology November 12

SYMPOSiUM REGiSTRATiON
www.chemotherapyfoundationsymposium.org
Cut off date for on-line registration is November 3

Registration Fees:
☐ $252. Physicians
☐ $125, Nurse, House Staff, Fellow Pharmacist, PA’s, NP’s, Industry
☐ $100, Mount Sinai and Affiliates
☐ $50, Tuesday or Saturday Only

*SPECIALTY*
☐ Hematology
☐ Oncology
☐ Pediatric Oncology
☐ Other

PLEASE Check the days/day you are attending:
☐ Wed-Fri (Full Symposium)
☐ Tues (Ped Oncology)
☐ Sat (Nursing)

*Those registering for the full Symposium pay NO ADDITIONAL FEE for the Tuesday or Saturday Sessions. No CME is issued for Saturday Sessions.

Register: ONLINE at www.chemotherapyfoundationsymposium.org
FAX this form to (212) 731-7930
MAIL completed form to:
Page & William Black Post-Graduate School
Mount Sinai School of Medicine, Box 1193
One Gustave L. Levy Pl, New York, NY 10029

*Check* Amount $ __________

Credit card # ____________
Exp. Date / / Signature __________

PLEASE make checks payable to Page & William Black Post-Graduate School

Name_________________________ Last Name_________________________ First Name_________________________
Address_________________________ City_________________________ State_________________________ Zip_________________________ Country_________________________
Tel: ( ) ___________________ FAX: ( ) ___________________

E-mail* __________________________

*E-mail required for confirmation and credit.
All Breakfast, Lunch and Dinner Events are Complimentary

For Further Information Contact:
Registration/CME Office: Gina Amatruda amatrudagina@sbcglobal.net
Conference Management Director: Jaclyn.silverman@mssm.edu
Phone 212 866 2813  Fax 212 369 5440
www.chemotherapyfoundationsymposium.org

REFUND POLICY
A 10% administrative charge plus a $15 processing fee will be deducted from all refunds issued. REQUESTS FOR REFUNDS RECEIVED AFTER NOVEMBER 4 WILL NOT BE HONORED by the Post-Graduate School.

Our Registration Fee has remained unchanged for ten years. This year because of economic circumstances, it has been raised for physicians. It is understood that registrations already made at the previous fee level will be honored.
Make your Hotel Reservations for the Symposium at Special Conference Rates

**MARRIOTT MARQUIS HOTEL**
Headquarters Hotel
1535 Broadway, New York, NY 10036-1654
Telephone 800 266 9432

**New On Line Reservation System at Symposium Headquarters Hotel**
https://resweb.passkey.com/go/chemotherapy2011
or call 800 266 9432

**SPECIAL DISCOUNT RATE $359**
A 14.75% sales tax and $3.50 per night occupancy tax is applicable to room rate.

To receive discounted group rate please make your reservations prior to October 11.

**MILLENNIUM HOTEL**
New York Broadway
145 West 44 Street at Broadway
New York, NY 10036
TEL 212 768 4400, 800 622 5569
FAX 212 789 7630

**SPECIAL DISCOUNT RATE $329**
A 14.75% sales tax and $3.50 per night occupancy tax is applicable to room rate.

Check in 4 PM. Check out 12 noon. A credit card or one night deposit is required to confirm a reservation. Late Reservations at Special Conference Rate are subject to availability.

**More Information**
If you prefer other hotel arrangements, please contact our Housing Manager, Denise Newman: Tel 718 835 4911, FAX 718 835 8661, E-mail Dnew229@aol.com

For additional information contact: dan.kavulish@mssm.edu
EXHIBITORS AND SUPPORTERS*

Abraxis Bioscience • ACT Biotech • Agennix
Algeta • Allos • Amgen • Ariad Merck
AstraZeneca • Bayer Healthcare • Biogen Idec
BioTheranostics • Boehringer Ingelheim
Bristol-Myers Squibb • CareMed • Carisis
Celator Pharmaceuticals • Celgene
Centocor Ortho Biotech • Cephalon
Champions Biotechnology • Daiichi Sankyo
Demos Publishing • Dendreon
DiagnoCure Labs • Eisai Inc • Exelixis
Express Scripts • Genentech BioOncology
Genomic Health • Genta • Genzyme • Gilead
GlaxoSmithKline • Immunomedics • Lilly Oncology
McMahon Publications • Merck • Merck Oncology
Micromet • Millennium Medical Publishing
Millennium: Takeda Oncology
Myriad Genetic Laboratories • Nektar
Novartis Oncology • NYU Medical Center
Oncomed • Onyx Pharmaceuticals
OSI Oncology • Pathwork Diagnostics
Pfizer Oncology • Pharmacyclics
Prometheus Laboratories • ProStrakan
Response Genetics • Sanofi-Aventis Oncology
Seattle Genetics
Sigma-Tau Pharmaceuticals
The Chemotherapy Foundation
Tisch Cancer Institute • US Labs • US Oncology
VP International • Ziopharm Oncology

*Some Commitments for 2011 are Pending.
Partners for Progress
New York Oncology Educational Alliance
Columbia University Medical Center
Long Island Jewish Medical Center
Montefiore-Einstein Cancer Center
Mount Sinai Medical Center
NYU Medical Center
SUNY Downstate Medical Center
Weill Medical College of Cornell University

FREE EDUCATIONAL PUBLICATIONS FROM THE CHEMOTHERAPY FOUNDATION

WHAT EVERY WOMAN AND HER DOCTOR SHOULD DISCUSS ABOUT OVARIAN CANCER - A MEDICAL ONCOLOGIST’S PERSPECTIVE
Ezra M. Greenspan, M.D., Founder of The Chemotherapy Foundation, Franco M. Muggia, M.D., Director, Medical Oncology, New York University School of Medicine, Chairman and Medical Director, The Chemotherapy Foundation.

WHAT EVERY MAN SHOULD KNOW ABOUT PROSTATE CANCER
Anna Ferrari, M.D., Co-Director, GU Cancer Program, New York University Medical Center

CHEMOTHERAPY TODAY – A Guide for Cancer Patients and Those Who Care About Them
Mary-Ellen Siegel, M.S.W., A.C.S.W., Clinical Instructor, Department of Community and Preventive Medicine, Mount Sinai School of Medicine, Social Work Consultant, The Chemotherapy Foundation, in collaboration with Franco M. Muggia, M.D. Professor of Medicine/Medical Oncology, New York University School of Medicine, Chairman and Medical Director, The Chemotherapy Foundation

Order from:
The Chemotherapy Foundation
183 Madison Avenue,
New York, NY 10016
Contact: scox@chemotherapyfoundation.org
Matthew D. Galsky, MD Assistant Professor of Medicine, Department of Medicine, Division of Hematology and Medical Oncology, Mount Sinai School of Medicine, Director, Geriatric/Geriatric Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, New York, NY

Lia Gore, MD Associate Professor of Pediatrics and Medicine, University of Colorado School of Medicine, Aurora, CO

Richard Gorlick MD Professor and Division Chief, Pediatric Hematology-Oncology at Albert Einstein Cancer Center and The Children’s Hospital at Montefiore, Bronx, NY

Paul E. Goss, MBChB, PhD Director, Breast Cancer Research, Co-Director, Breast Cancer Disease Program, DF/HCC, Massachusetts General Hospital, Boston, MA

Noah M. Hahn, MD Assistant Professor, Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN

Missak Haigentz, Jr., MD Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Associate Professor of Clinical Otorhinolaryngology - Head & Neck Surgery, Department of Otorhinolaryngology - Head & Neck Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY

Simon J. Hall, MD Associate Professor & Chair, Urology, Assistant Professor, Gene and Cell Medicine, Mount Sinai Medical Center, New York, NY

Daniel F. Hayes, MD Professor, Clinical Director, Breast Oncology Program, Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Ronald B. Herberman, MD Founding Director Emeritus, University of Pittsburgh Cancer Institute, Pittsburgh, PA

Howard S. Hochster, MD Associate Director, Yale Cancer Center, Professor of Medicine, Yale School of Medicine, New Haven, CT

Paulo M. Hoff, MD FACP Chairman of Medical Oncology, Instituto do cancer de Sao Paulo Otitao Fria de Oliveira, University of Sao Paulo, Executive Director, Centro de Oncologia, Hospital Sirio Libanes, Sao Paulo, Brazil

Ronald Hoffman, MD Professor, Medicine, Hematology and Medical Oncology, Professor Gene and Cell Medicine, Mount Sinai School Of Medicine, New York, NY

James F. Holland, MD Professor, Medicine, Hematology and Medical Oncology, Professor, Oncological Sciences, Mount Sinai Medical Center, New York, NY

Scott C. Howard, MD, MSc Associate Professor, University of Tennessee College of Medicine, Associate Member, St. Jude Children’s Research Hospital, Memphis, TN

Clifford A. Hudis, MD Chief of the Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY

Kevin S. Hughes, MD Associate Professor of Surgery, Harvard Medical School, Surgical Director, Breast Screening, Co-Director, Avon Comprehensive Breast Evaluation Center, Medical Director, Bermuda Cancer Genetics and Risk Assessment Clinic, Massachusetts General Hospital, Boston, MA

Steven H. Itzkowitz, MD Professor of Medicine, Associate Director of The Dr. Henry D. Janowitz Division of Gastroenterology, Director of the GI Fellowship Program at Mount Sinai School of Medicine, New York, NY

Hagop M. Kantarjian, MD Professor of Medicine, Internist, Department of Leukemia, , Chairman & Professor, Leukemia Department, MD Anderson Cancer Center, Houston, TX

Laurence Kotz, MD Professor of Surgery, University of Toronto, Chairman, World Uro-Oncology Federation, Chief of Urology, Sunnybrook Health Sciences Centre, Toronto, Canada

Brian H. Kushner, MD Attending Physician and Member, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY

Jeffrey E. Lancet, MD Associate Member, Leukemia Section Chief, Moffitt Cancer Center, Tampa, FL

Corey J. Langer, MD Professor of Medicine, Hematology-Oncology Division, Abramson Cancer Center of the University of Pennsylvania, Department of Medical Oncology, Medical Director Thoracic Oncology, Director of Research, Fox Chase Cancer Center, Philadelphia, PA

John P. Leonard, MD Associate Professor of Medicine, Clinical Director, Center for Lymphoma and Myeloma, Weill Cornell Medical College of Cornell University, New York Presbyterian Hospital, New York, NY

Stuart M. Lichtman, MD, FACMP Medical Oncologist, NCCN Guidelines Taskforce for the treatment and Evaluation of Older Women with Breast Cancer, 65+ Clinical Geriatric Group, Cancer and Aging Program, Memorial Sloan-Kettering Cancer Center, New York, NY

Allan Lipton, MD Professor of Medicine and Oncology, Medicine-Division of Hematology Oncology, M.S. Hershey Medical Center, Hershey, PA

Jochen H. Lorch, MD, MSc Clinical Instructor, Department of Medicine, Harvard Medical School, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Robert G. Maki, MD, PhD Senior Faculty, Medicine, Pediatrics, Hematology/Oncology, Mount Sinai School Of Medicine, New York, NY

Vicky Makker, MD Assistant Attending Physician, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY

John L. Marshall, MD Division Chief, Associate Professor of Medicine, Chief, Division of Hematology/Oncology, Georgetown University Hospital, Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center, Washington, DC

David F. McDermott, MD Lecturer, Department of Cell Biology, Harvard Medical School, Staff Physician, Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA

William P. McGuire, MD Director, Weinberg Cancer Institute, Professor of Medicine and Oncology, Georgetown University, Baltimore, MD
The Chemotherapy Foundation
The Chemotherapy Foundation, a non-profit organization, supports laboratory and clinical research projects at major medical institutions, symposia for the profession, and publishes informative booklets for the profession and the public. Tax-deductible contributions may be sent to 183 Madison Avenue, New York, NY 10016.

Chairman and Medical Director
President
Franco Muggia, M.D.
Barry Richter

Director of Medical Symposia
Edward Ambinder, M.D.
Edward Ambinder, M.D.

Associate Medical Directors
Silvia Formenti, M.D.
Janice Gabrilove, M.D.
Howard Hochster, M.D.
Steven Itzkowitz, M.D.
Roman Perez-Soler, M.D.

Executive Director
Shirley Cox

Conference Management Director
Jaclyn Silverman

Clinical Advisory Board
Chandra Bellani, MD
Penn State Cancer Institute

Jordan Berlin, MD
Vanderbilt-Ingram Cancer Center

Howard Burris, MD
Sarah Cannon Cancer Center

Harold Burstein, MD
Dana Farber Cancer Institute

Nicoletta Colombo, MD
European Institute of Oncology

Anna Ferrari, MD
New York University School of Medicine

Howard Hochster, MD
Yale Cancer Center

Larry Norton, MD
Memorial Sloan-Kettering Cancer Center

William Oh, MD
Tisch Cancer Institute, Mount Sinai School of Medicine

Kanti Rai, MD
Long Island Jewish Hospital, New York

The collaboration of the Tisch Cancer Institute and the NYU Oncology Division in developing the Agenda for the 2011 Symposium is appreciated.

Special Projects
Steven Berns, MD
Tisch Cancer Institute

Sonia Reichen, MD
Tisch Cancer Institute

CONTACT INFORMATION
Symposium
Jaclyn.silverman@mssm.edu 212 866 2813

New Perspectives in Oncology Practice
Gina Amatruda amatrudagina@sbcglobal.net

SYMPOSIUM CALENDAR
2012 November 6-10 • 2013 November 5-9
MARRIOTT MARQUIS
WELCOME BACK NEXT YEAR
www.chemotherapyfoundationsymposium.org
Chemotherapy Foundation Symposium
Innovative Cancer Therapy for Tomorrow®
November 6-12, 2011
New York City, USA